Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children

Background: Tacrolimus is a potent immunosuppressant used in organ transplant recipients; an ointment formulation is being developed as a therapeutic agent for atopic dermatitis. Objective: Our purpose was to define the pharmacokinetics and evaluate tacrolimus 0.3% ointment as therapy for moderate t...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Academy of Dermatology Vol. 38; no. 1; pp. 69 - 76
Main Authors:	Alaiti, Samer, Kang, Sewon, Fiedler, Virginia C., Ellis, Charles N., Spurlin, David V., Fader, Darrell, Ulyanov, Grigoriy, Gadgil, Shrikant D., Tanase, Atsushi, Lawrence, Ira, Scotellaro, Patricia, Raye, Kathleen, Bekersky, Ihor
Format:	Journal Article
Language:	English
Published:	New York, NY Mosby, Inc 1998 Elsevier
Subjects:	Administration, Cutaneous Adolescent Adult Aged Area Under Curve Biological and medical sciences Biological Availability Child Child, Preschool Dermatitis, Atopic - drug therapy Female Flushing - chemically induced Follow-Up Studies Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - blood Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Incidence Injections, Intravenous Male Medical sciences Middle Aged Ointments Pharmacology. Drug treatments Remission Induction Sensation Disorders - etiology Skin, nail, hair, dermoskeleton Tacrolimus - administration & dosage Tacrolimus - adverse effects Tacrolimus - blood Tacrolimus - pharmacokinetics Tacrolimus - therapeutic use Vasodilation - drug effects Human Allergy Immunopathology Skin disease Chemotherapy Treatment Tacrolimus Atopic dermatitis Immunosuppressive agent Topical administration Atopy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background: Tacrolimus is a potent immunosuppressant used in organ transplant recipients; an ointment formulation is being developed as a therapeutic agent for atopic dermatitis. Objective: Our purpose was to define the pharmacokinetics and evaluate tacrolimus 0.3% ointment as therapy for moderate to severe atopic dermatitis. Methods: Thirty-nine patients, 5 to 75 years of age, received 14 applications over 8 days. Serial blood samples were collected on days 1 and 8, with predose samples collected on days 2 through 7. Overall response and signs/symptoms were rated daily on days 1 through 11. Incidence of adverse events and laboratory profile were determined. Results: Mean area under the curve (0.9 to 42.5 ng ·hr/ml) was highly variable and appeared to be related to size of application area. No systemic accumulation of tacrolimus was observed. Comparison to historical intravenous data indicates that absolute bioavailability of topical tacrolimus was less than 0.5%. Ninety-five percent of patients showed at least good improvement. All adverse events were transient. Burning was the most common application site adverse event and vasodilatation ("flushing/warmth") was the most common nonapplication site adverse event. No drug-related changes in laboratory profile were observed. Conclusion: The results of this study suggest that tacrolimus 0.3% ointment may be a safe and effective therapy for atopic dermatitis. (J Am Acad Dermatol 1998;38:69-76.)
ISSN:	0190-9622 1097-6787
DOI:	10.1016/S0190-9622(98)70541-9